Showing results (1941-1950 of 2,460) with videos related to

Sort By:
Pageof 246
Journal of Proteome Research|December 21, 2007
Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subsetThomas O Metz, Wei-Jun Qian, Jon M Jacobs, et al.
International Immunopharmacology|February 8, 2012
Arsenic decreases RXRα-dependent transcription of CYP3A and suppresses immune regulators in hepatocytesTrisha L Noreault-Conti, Abigail Fellows, Judith M Jacobs, et al.
Molecular Therapy. Methods & Clinical Development|March 28, 2017
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T CellsMalika Hale, Baeckseung Lee, Yuchi Honaker, et al.
Brain : a Journal of Neurology|February 1, 1987
Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelinationP K Thomas, R W Walker, P Rudge, et al.
Biochimica Et Biophysica Acta. Proteins and Proteomics|June 13, 2021
Phosphoproteomic response of cardiac endothelial cells to ischemia and ultrasoundUchenna Emechebe, David Giraud, Azzdine Y Ammi, et al.
Scientific Reports|September 15, 2017
Toll-like receptor 2 induced cytotoxic T-lymphocyte-associated protein 4 regulates Aspergillus-induced regulatory T-cells with pro-inflammatory characteristicsRuud P H Raijmakers, Evelien G G Sprenkeler, Floor E Aleva, et al.
Transfusion|November 14, 2014
Anti-SSA antibodies are present in immunoglobulin preparationsRenate G van der Molen, Dörte Hamann, Joannes F M Jacobs, et al.
JOR Spine|June 26, 2023
Biomechanical evaluation of a novel biomimetic artificial intervertebral disc in canine cervical cadaveric spinesCelien A M Jacobs, Remco J P Doodkorte, S Amir Kamali, et al.
Data in Brief|September 16, 2021
(Phospho)Proteomic dataset of ischemia- and ultrasound- stimulated mouse cardiac endothelial cells in vitroUchenna Emechebe, David Giraud, Azzdine Y Ammi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinomaD P S Sohal, K Mykulowycz, T Uehara, et al.
Pageof 246